Base-case analysis results indicate that pathway 1—in which patients intensify to triple therapy with DPP-4 inhibitors and SGLT2 inhibitors before transitioning to triple therapy with DPP-4 ...

This elevated risk equated to a bullous pemphigoid incidence rate of 0.42 among DPP-4 inhibitor users versus 0.31 for sulfonylurea users per 1,000 person-years, they wrote in JAMA Dermatology.

New research linking dipeptidyl peptidase-4 (DPP-4) inhibitors used to treat type 2 diabetes to an increased risk for inflammatory bowel disease (IBD) is prompting investigators to urge monitoring ...

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape. Cite this: Generic DPP-4 Inhibitors Would Be a 'Shot in the Arm' - Medscape - Feb 08 ...

Results showed that DPP-4 inhibitors yielded 0.42 cases of bullous pemphigoid per 1,000 person-years compared with 0.31 cases per 1,000 person-years for sulfonylureas (HR = 1.42; 95% CI, 1.17-1.72).

There was a similar risk of lower limb amputation and bone fractures as with DPP-4 inhibitors. In addition, there was an increased risk of diabetic ketoacidosis, which is consistent with ...

Researchers noted fDPP-4 discriminated clinical activity from remission with areas under the curve of 0.8 (95% CI, 0.68-0.93) and 0.76 (95% CI, 0.58-0.94) in patients with UC and CD, respectively.

In the study, empagliflozin demonstrated a 22% relative risk reduction in all-cause hospitalizations vs DPP-4 inhibitors after a mean follow-up of 5.4 months.

Researchers used the IQVIA Core Diabetes Model (CDM) to evaluate empagliflozin against sitagliptin (Januvia) and saxagliptin (Onglyza), both from the dipeptidyl peptidase-4 (DPP-4) inhibitor class.